Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Allergo Journal
Erschienen in: Allergo Journal 5/2020

10.08.2020 | Anaphylaxie | Übersicht

Hypersensitivity reactions to biologics (part II): classifications and current diagnostic and treatment approaches*

verfasst von: Askin Gülsen, Prof. Dr. med. Bettina Wedi, Prof. Dr. med. Uta Jappe

Erschienen in: Allergo Journal | Ausgabe 5/2020

Einloggen, um Zugang zu erhalten

Auszug

Submitted …
Literatur
1.
Scherer K, Spoerl D, Bircher AJ. Adverse drug reactions to biologics. J Dtsch Dermatol Ges. 2010;8(6):411-26
2.
Vultaggio A, Petroni G, Pratesi S, Nencini F, Cammelli D, Ferraro A, et al. How the immune system responds to therapeutic biological agents. J Int Med Res. 2016;44:38-42
3.
Flood-Page P, Swenson C, Faiferman I, Matthews J, Williams M, Brannick L, et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med. 2007;176:1062-71
4.
Ferrer M, Madamba R. Biologics in chronic urticaria. Allergol Immunopathol (Madr). 2017;45:41-4
5.
Kawalec P, Holko P, Moćko P, Pilc A. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis. Rheumatol Int. 2018;38:189-201
6.
7.
8.
Jappe U. Allergic reactions to oncology biologics. Allergo-Oncology Section of EAACI Congress; Munich. 2018
9.
Casale TB. Biologics and biomarkers for asthma, urticaria, and nasal polyposis. J Allergy Clin Immunol. 2017;139:1411-21
10.
Pichler WJ. Adverse side-effects to biological agents. Allergy. 2006;61:912-20
11.
Barbaud A, Granel F, Waton J, Poreaux C. How to manage hypersensitivity reactions to biological agents? Eur J Dermatol. 2011;21:667-74
12.
Shimabukuro-Vornhagen A, Gödel P, Subklewe M, Stemmler HJ, Schlößer HA, Schlaak M, et al. Cytokine release syndrome. J Immunother Cancer. 2018;6(1):56
13.
Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006;355:1018
14.
Vultaggio A, Castells MC. Hypersensitivity reactions to biologic agents. Immunol Allergy Clin North Am. 2014;34:615-32
15.
Chung CH. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist. 2008;13:725-32
16.
Boven K, Knight J, Bader F, Rossert J, Eckardt KU, Casadevall N. Epoetin-associated pure red cell aplasia in patients with chronic kidney disease: solving the mystery. Nephrol Dial Transplant. 2005;20(Suppl 3):iii33-40. Erratum in: Nephrol Dial Transplant. 2006;21:2678
17.
Pascual-Salcedo D, Plasencia C, Ramiro S, Nuño L, Bonilla G, Nagore D, et al. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology. 2011;50:1445-52.
18.
Atiqi S, Hooijberg F, Loeff FC, Rispens T, Wolbink GJ. Immunogenicity of TNF-Inhibitors. Front Immunol. 2020;11:312.
19.
Maggi E, Vultaggio A, Matucci A. Acute infusion reactions induced by monoclonal antibody therapy. Expert Rev Clin Immunol. 2011;7:55-63
20.
Benucci M, Grossi V, Manfredi M, Damiani A, Infantino M, et al. Laboratory Monitoring of Biological Therapies in Rheumatology: The Role of Immunogenicity. Ann Lab Med 2020; 40:101-13
21.
Ramos-Casals M, Brito-Zerón P, Muñoz S, Soria N, Galiana D, Bertolaccini L, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore). 2007;86:242-51
22.
Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist. 2007;12:601-9
23.
Gell PGH, Coombs RRA. The classification of allergic reactions underlying disease. In: Coombs RRA, Gell PGH, editors. Clinical aspects of immunology. Oxford: Blackwell Science; 1963. pp. 317-37
24.
Uzzaman A, Cho SH. Chapter 28: Classification of hypersensitivity reactions. Allergy Asthma Proc. 2012;33:96-9
25.
Ring J, Messmer K. Incidence and severity of anaphylactoid reactions to colloid volume substitutes. Lancet. 1977;1(8009):466-9
26.
Ring J, Beyer K, Biedermann T, Bircher A, Duda D, Fischer J et al. Guideline for acute therapy and management of anaphylaxis. S2 guideline of DGAKI, AeDA, GPA, DAAU, BVKJ, ÖGAI, SGAI, DGAI, DGP, DGPM, AGATE and DAAB. Allergo J Int 2014; 23: 96-112
27.
Banchereau J, Pascual V, Palucka AK. Autoimmunity through cytokine-induced dendritic cell activation. Immunity. 2004;20:539-50
28.
Peréz-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: Is there a silver lining? J Clin Oncol. 2005;23:5235-46
29.
Weng MS, Chang JH, Hung WY, Yang YC, Chien MH. The interplay of reactive oxygen species and the epidermal growth factor receptor in tumor progression and drug resistance. J Exp Clin Cancer Res. 2018;37:61
30.
Sinagra E, Perricone G, Romano C, Cottone M. Heart failure and anti tumor necrosis factor-alpha in systemic chronic inflammatory diseases. Eur J Intern Med. 2013;24:385-92
31.
Al-Huthail YR. Neuropsychiatric side-effects of interferon alfa therapy for hepatitis C and their management: a review. Saudi J Gastroenterol. 2006;12:59-67
32.
Mathur G, Singh DV, Singal A. Unusual course of interferon-related retinopathy in chronic hepatitis C. Oman J Ophthalmol. 2016;9:189-90
33.
Hsu Blatman KS, Castells MC. Desensitizations for chemotherapy and monoclonal antibodies: indications and outcomes. Curr Allergy Asthma Rep. 2014;14:453
34.
Isabwe GAC, de Las Vecillas Sanchez L, Castells M. Management of adverse reactions to biologic agents. Allergy Asthma Proc. 2017;38:409-18
35.
Corominas M, Gastaminza G, Lobera T. Hypersensitivity reactions to biological drugs. J Investig Allergol Clin Immunol. 2014;24:212-25
36.
Picard M, Galvão VR. Current Knowledge and Management of Hypersensitivity Reactions to Monoclonal Antibodies. J Allergy Clin Immunol Pract. 2017;5:600-9
37.
Castells M. Drug hypersensitivity and anaphylaxis in cancer and chronic inflammatory diseases: the role of desensitizations. Front Immunol. 2017;8:1472
38.
Cox L, Lieberman P, Wallace D, Simons FE, Finegold I, Platts-Mills T, et al. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma & Immunology Omalizumab-Associated Anaphylaxis Joint Task Force follow-up report. J Allergy Clin Immunol. 2011;128:210-2
39.
Lieberman P, Rahmaoui A, Wong DA. The safety and interpretability of skin tests with omalizumab. Ann Allergy Asthma Immunol. 2010;105:493-5
40.
Galvão VR, Castells MC. Hypersensitivity to biological agents-updated diagnosis, management, and treatment. J Allergy Clin Immunol Pract. 2015;3:175-85
41.
Aberer W, Bircher A, Romano A, Blanca M, Campi P, Fernandez J. European Network for Drug Allergy (ENDA); EAACI interest group on drug hypersensitivity. Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations. Allergy. 2003;58:854-63
42.
Vultaggio A, Matucci A, Nencini F, Pratesi S, Parronchi P, Rossi O, et al. Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. Allergy. 2010;65:657-61
43.
Vultaggio A, Matucci A, Nencini F, Pratesi S, Maggi E. Skin testing and infliximab-specific antibodies detection as a combined strategy for preventing infusion reaction. Intern Emerg Med. 2012;7:77-9
44.
Cazzola M, Matera MG, Levi-Schaffer F, Rogliani P. Safety of humanized monoclonal antibodies against IL 5 in asthma: focus on reslizumab. Expert Opin Drug Saf. 2018;17:429-35
45.
Matucci A, Nencini F, Pratesi S, Maggi E, Vultaggio A. An overview on safety of monoclonal antibodies. Curr Opin Allergy Clin Immunol. 2016;16:576-81
46.
Homann A, Röckendorf N, Kromminga A, Frey A, Jappe U. B cell epitopes on infliximab identified by oligopeptide microarray with unprocessed patient sera. J Transl Med. 2015;13:339
47.
Homann A, Röckendorf N, Kromminga A, Frey A, Platts-Mills T, Jappe U. Distinct glycan and peptide IgE epitopes of the TNF-alpha blockers infliximab and adalimumab—precision diagnostics by cross-reactivity immune profiling of patient sera. Theranostics. 2017;7:4699-709
48.
Steenholdt C, Svenson M, Bendtzen K, Thomsen OØ, Brynskov J, Ainsworth MA. Acute and delayed hypersensitivity reactions to infliximab and adalimumab in a patient with Crohn's disease. J Crohns Colitis. 2012;6:108-11
49.
Somerville L, Bardelas J, Viegas A, D'Andrea P, Blogg M, Peachey G. Immunogenicity and safety of omalizumab in pre-filled syringes in patients with allergic (IgE-mediated) asthma. Curr Med Res Opin. 2014;30:59-66
50.
Baker DL, Nakamura GR, Lowman HB, Fischer SK. Evaluation of IgE antibodies to omalizumab (Xolair®) and their potential correlation to anaphylaxis. AAPS J. 2016;18:115-23
51.
Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha 1,3 galactose. N Engl J Med. 2008;358:1109-17
52.
Jappe U, Minge S, Kreft B, Ludwig A, Przybilla B, Walker A, et al. Meat allergy associated with galactosyl-α-(1,3)-galactose (α-Gal)—closing diagnostic gaps by anti-α-Gal IgE immune profiling. Allergy. 2018;73:93-105
53.
Joshi SR, Khan DA. Anaphylaxis induced by biologics. Curr Treat Options Allergy. 2019;6:125-41
54.
Singh SK, Mahler HC, Hartman C, Stark CA. Are injection site reactions in monoclonal antibody therapies caused by polysorbate excipient degradants? J Pharm Sci. 2018;107:2735-41
55.
Palacios Castaño MI, Venturini Díaz M, Lobera Labairu T, González Mahave I, Del Pozo Gil MD, et al. Anaphylaxis due to the excipient polysorbate 80. J Investig Allergol Clin Immunol. 2016;26:394-6
56.
Hemmings O, Kwok M, McKendry R, Santos AF. Basophil activation test: old and new applications in allergy. Curr Allergy Asthma Rep. 2019;19:58
57.
Piva E, Chieco-Bianchi F, Krajcar V, Aversa S, Plebani M. Adverse reactions in patients with B cell lymphomas during combined treatment with rituximab: in vitro evaluation of rituximab hypersensitivity by basophil activation test. Am J Hematol. 2012;87:130-1
58.
Iwamoto T, Okamoto A, Ishinaga H, Shimizu K, Gayle AA, Takeuchi K, et al. A novel approach to predict cetuximab-induced hypersensitivity reaction: detection of drug-specific IgE on basophils. Cancer Med. 2016;5:1004-12
59.
Kim SY, Kim JH, Jang YS, Choi JH, Park S, Hwang YI, et al. The basophil activation test is safe and useful for confirming drug-induced anaphylaxis. Allergy Asthma Immunol Res. 2016;8:541-4
60.
Vultaggio A, Matucci A, Parronchi P, Rossi O, Palandri F, Romagnani S, et al. Safety and tolerability of infliximab therapy: suggestions and criticisms based on wide clinical experience. Int J Immunopathol Pharmacol. 2008;21:367-74
61.
Vogel WH. Infusion reactions: diagnosis, assessment and management. Clin J Oncol Nurs. 2010;14:10-21
62.
Matucci A, Cammelli D, Cantini F, Goletti D, Marino V, Milano GM, et al. Influence of anti-TNF immunogenicity on safety in rheumatic disease: a narrative review. Expert Opin Drug Saf. 2016;15:3-10
63.
Quercia O, Emiliani F, Foschi FG, Stefanini GF. Adalimumab desensitization after anaphylactic reaction. Ann Allergy Asthma Immunol. 2011;106:547-8
64.
Stallmach A, Giese T, Schmidt C, Meuer SC, Zeuzem SS. Severe anaphylactic reaction to infliximab: successful treatment with adalimumab - report of a case. Eur J Gastroenterol Hepatol. 2004;16:627-30
65.
Moss IB, Moss MB, dos Reis DS, Coelho RM. Immediate infusional reactions to intravenous immunobiological agents for the treatment of autoimmune diseases: experience of 2126 procedures in a non-oncologic infusion centre. Rev Bras Reumatol. 2014;54:102-9
66.
67.
Mersin SS, Bulut I, Yakut T, Örçen C, Tepetam FM. Successful desensitization with panitumumab; a case report. Allergy. 2019;74:741-2
68.
Soyyiğit Ş, Kendirlinan R, Aydın O, Çelik GE. Successful desensitization with anakinra in a case with immediate hypersensitivity reaction. Ann Allergy Asthma Immunol. 2014;113:325-6
69.
Gutiérrez-Fernández D, Saldaña-Valderas M, de la Varga-Martínez R, Foncubierta-Fernández A, Fernández-Anguita MJ, Fernández-Valle MDC, et al. Hypersensitivity to alemtuzumab. A safe and effective desensitization protocol: a case report. J Oncol Pharm Pract. 2019;25:1016-20
70.
Williams SJ, Khokhar A, Gharib A. Successful rapid desensitization to intravenous bevacizumab using a 14-step protocol: case report. J Allergy Clin Immunol Pract. 2017;5:1746-7
71.
Di Girolamo A, Albanesi M, Sinisi A, Nettis E, Di Bona D, Caiaffa MF, et al. Rapid desensitization for brentuximab vedotin (Adceteris®) allergy: a case report. Clin Mol Allergy. 2018;16:22
72.
Giavina-Bianchi P, Aun MV, Galvão VR, Castells M. Rapid desensitization in immediate hypersensitivity reaction. Curr Treat Options Allergy. 2015;2:268-85
73.
Cortellini G, Mascella F, Simoncelli M, Lippolis D, Focherini MC, Cortellini F, et al. Effective desensitization to tocilizumab in delayed hypersensitivity reaction. Pharmacology. 2018;102:114-6
74.
Wang CS, Liverman RS, Garro R, George RP, Glumova A, Karp A, et al. Ofatumumab for the treatment of childhood nephrotic syndrome. Pediatr Nephrol. 2017;32:835-41
75.
Sáenz de Santa María García M, Noguerado-Mellado B, Rojas-Pérez-Ezquerra P, Prieto-García A, Bartolomé-Zavala B, Tornero P. First case of allergy to nivolumab. J Allergy Clin Immunol Pract. 2017;5:1140-1
76.
HemOnc.org - A Free Hematology/Oncology Reference. Rituximab (Rituxan) desensitization protocol. https://​hemonc.​org/​wiki/​Rituximab_​(Rituxan)_desensitization_protocol and https://hemonc.org/w/images/2/2f/Ritixumab_desensitization_spreadsheet.xls. Accessed 30 Apr 2020
77.
Castells M. Rapid desensitization for hypersensitivity reactions to medications. Immunol Allergy Clin North Am. 2009;29:585-606
78.
Castells M. Drug desensitization in oncology: chemotherapy agents and monoclonal antibodies. In: Pichler WJ, editor. Drug hypersensitivity. Basel: Karger; 2007. pp. 413-25
79.
Khan DA. Hypersensitivity and immunologic reactions to biologics: opportunities for the allergist. Ann Allergy Asthma Immunol. 2016;117:115-20
80.
Brown SG. Clinical features and severity grading of anaphylaxis. J Allergy Clin Immunol. 2004;114:371-6
Metadaten
Titel
Hypersensitivity reactions to biologics (part II): classifications and current diagnostic and treatment approaches*
verfasst von
Askin Gülsen
Prof. Dr. med. Bettina Wedi
Prof. Dr. med. Uta Jappe
Publikationsdatum
10.08.2020
Verlag
Springer Medizin
Schlagwörter
Anaphylaxie
Anaphylaxie
Erschienen in
Allergo Journal / Ausgabe 5/2020
Print ISSN: 0941-8849
Elektronische ISSN: 2195-6405
DOI
https://doi.org/10.1007/s15007-020-2567-5

Weitere Artikel der Ausgabe 5/2020

Allergo Journal 5/2020 Zur Ausgabe

Panorama

Snus weniger gefährlich als Rauchen

Pharmaforum

Pollenflug oder Corona? Videosprechstunden von Allergikern stark nachgefragt

AeDA/DGAKI informieren

Noch mehr Programm-Highlights

Literatur kompakt

Allergische Rhinitis: Lebensqualität unter SCIT und SLIT bei Kindern vergleichbar

Pharmaforum

Anti-IgE-Antikörper bei csU: komplette Symptomkontrolle bei jedem Zweiten

Pharmaforum

Allergien bei Kindern: Frühzeitige spezifische Immuntherapie verhindert atopischen Marsch

Passend zum Thema

ANZEIGE
Anaphylaxie

Es wäre so einfach, ein Leben zu retten – Wenn man nur daran denkt…

Anaphylaxie ist eine akute schwere allergische Reaktion und somit die schwerste Komplikation in der Allergologie. Darauf sollten Ärztinnen und Ärzte vorbereitet sein.

Bildnachweise